Arcturus Therapeutics Holdings Inc To Present At Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day Transcript
Okay. Great. Well, good afternoon, everyone. Thanks for joining us for another fireside chat discussion. Here to my left are Arcturus' CEO, Joe Payne. And to his left is CFO, Andy Sassine. I'm Seamus Fernandez, one of the biopharma analysts here at Guggenheim Securities. And this is our annual rare disease and genetic medicines conference. So in that context, of course, as an mRNA company, we sort of have to start with vaccines, and then we'll jump right into the rare disease side of things.
Questions & Answers
So Joe, maybe just to start us off, I will start with a couple of vaccines questions. So on the cusp of data from Meiji in the head-to-head trial, maybe you can just recap the design of the study for investors. And then maybe just help us understand what success might look like from an approval standpoint and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
